Alterity Therapeutics secures leading neurodegenerative disease expert for pivotal trial phase
Alterity Therapeutics (ASX: ATH) has appointed Dr. Daniel O. Claassen as Chief Medical Advisor, effective March 2026. Dr. Claassen, who served as coordinating investigator for the company’s Phase 2 ATH434 trial, will retain his academic position at Vanderbilt University Medical Center whilst advising the company ahead of its Phase 3 pivotal trial in Multiple System Atrophy (MSA).
The appointment brings continuity and specialised expertise to Alterity’s clinical development programme. Dr. Claassen’s intimate knowledge of the ATH434 programme, combined with more than two decades of clinical and translational research experience in movement disorders, positions him to guide the company through the critical transition from Phase 2 efficacy data to pivotal trial execution.
Dr. Claassen is a board-certified neurologist who has authored hundreds of peer-reviewed publications and secured sustained competitive grant funding from agencies including the National Institutes of Health, the U.S. Department of Defense, and numerous foundations. His appointment signals strategic preparation for a capital-intensive Phase 3 trial in a rare disease indication where clinical expertise and regulatory credibility are essential.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
What does a Chief Medical Advisor do in biotech?
A Chief Medical Advisor (CMA) serves as a senior clinical and regulatory strategist in drug development companies. The role bridges scientific research, clinical trial execution, and regulatory compliance.
For investors, the CMA function reduces execution risk during pivotal studies by ensuring trial protocols are scientifically robust, ethically sound, and aligned with regulatory expectations. Active clinicians in CMA roles bring real-world patient experience that purely corporate executives may lack, strengthening relationships with regulators and key opinion leaders in the medical community.
The core responsibilities of a Chief Medical Advisor typically include:
- Trial Design Guidance – Advising on clinical protocol development, endpoint selection, and patient recruitment strategies to maximise the probability of regulatory success.
- Regulatory Input – Providing medical perspective during interactions with regulatory bodies such as the FDA or TGA, translating clinical findings into language that supports approval pathways.
- Medical Oversight – Monitoring patient safety data throughout trials and advising on risk-benefit assessments as new information emerges.
Academic credibility matters particularly in rare disease development, where small patient populations require precise trial design and where physician networks often drive patient referrals into studies.
Dr. Claassen’s credentials and MSA expertise
Dr. Claassen is Professor of Neurology at Vanderbilt University Medical Center, where he previously served as Chief of the Division of Behavioral and Cognitive Neurology. His clinical focus centres on movement disorders and cognitive neuroscience, with particular emphasis on neurodegenerative diseases including MSA, the exact condition ATH434 targets.
His research programme spans clinical trials, translational neuroscience, and biomarker discovery. Dr. Claassen has served as principal investigator on numerous clinical trials, working across academic medical centres and industry partnerships to advance therapies for neurodegenerative disorders. He directs a laboratory investigating the biological mechanisms of neurodegeneration through advanced neuroimaging, cognitive neuroscience, and patient-derived biomarkers.
Dr. Claassen also serves as Chief Executive Officer of the Huntington’s Study Group, where he oversees international research initiatives and organisational strategy to accelerate therapy development. This leadership role demonstrates strategic and operational capability beyond purely clinical expertise.
Dr. Daniel O. Claassen
“Serving as Chief Medical Advisor for Alterity represents a unique opportunity to translate my academic research and clinical trial experience into the development of new treatments for neurodegenerative diseases. Given the urgent need for disease-modifying therapies and the clinically meaningful slowing of multiple system atrophy progression observed with ATH434 in Phase 2, I am excited to help advance this program into a pivotal trial.”
Why this appointment matters for ATH434’s Phase 3
Dr. Claassen’s appointment directly addresses execution risk in Alterity’s upcoming Phase 3 pivotal trial. As the coordinating investigator for the Phase 2 study, he possesses institutional knowledge of ATH434’s clinical profile, trial infrastructure, and investigator network. This continuity reduces knowledge loss during the transition to pivotal development.
ATH434 demonstrated clinically meaningful efficacy in a randomised, double-blind, placebo-controlled Phase 2 clinical trial. The company has further reported positive data from an open-label Phase 2 clinical trial in participants with advanced MSA. Embedding the Phase 2 coordinating investigator at leadership level strengthens protocol design and regulatory strategy for Phase 3.
Phase 3 trials represent major capital deployment and binary value inflection points. Having an expert who understands the drug’s mechanism, patient population, and clinical assessment tools reduces trial design errors that could compromise statistical power or regulatory acceptance.
Leadership commentary on strategic timing
David Stamler, Chief Executive Officer of Alterity Therapeutics, emphasised the significance of this appointment ahead of the company’s Phase 3 preparations.
David Stamler, MD, CEO
“I am thrilled to welcome Dr. Claassen as our new Chief Medical Advisor, bringing deep clinical and development expertise to our organization at a pivotal time for Alterity. Daniel’s highly distinguished track record focused on patient care and clinical trial conduct in neurodegenerative diseases will be invaluable as we advance ATH434 into Phase 3. Daniel was the coordinating investigator for our Phase 2 study and has been a key contributor to our ATH434 program in multiple system atrophy from the outset, so he is exceptionally well qualified to help guide our next phase of growth and execution.”
The appointment’s timing reflects preparation for near-term Phase 3 initiation. Dr. Claassen’s role commences in March 2026, positioning him to contribute to final protocol design, site selection, and regulatory filing strategy ahead of patient recruitment.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
Alterity’s pipeline and upcoming catalysts
Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for Multiple System Atrophy and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive neurodegenerative disease.
ATH434, the company’s lead asset, has demonstrated clinically meaningful efficacy in Phase 2 trials. Alterity also maintains a drug discovery platform generating patentable chemical compounds to treat underlying pathology in neurological diseases. The company is based in Melbourne, Australia, and San Francisco, California, USA.
| Asset | Indication | Development Stage |
|---|---|---|
| ATH434 | Multiple System Atrophy (MSA) | Phase 3 preparation |
| Discovery Platform | Neurological diseases | Preclinical |
Phase 3 initiation represents a major value inflection point for the company. The appointment of an internationally recognised MSA expert with direct ATH434 programme experience signals operational readiness to execute on this pivotal catalyst.
The combination of academic credibility, MSA-specific expertise, and intimate knowledge of ATH434’s clinical development history positions Dr. Claassen to guide Alterity through the critical transition from promising Phase 2 data to pivotal Phase 3 execution. For investors, this appointment reduces key-person risk and strengthens the probability of successful trial design ahead of the company’s most significant clinical milestone.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to receive market-moving announcements the moment they drop, with the analysis already done for you.